International Prognostic Score for Asymptomatic Early-stage CLL (IPS-E)
Evaluates prognosis of asymptomatic early-stage chronic lymphocytic leukemia (CLL).
Advice
- Patients with low scores may be suitable for regular monitoring without immediate treatment, reinforcing the "watch and wait" approach.
- Higher scores indicate a greater risk of disease progression and may suggest a need for more frequent monitoring or consideration of early therapeutic interventions, including novel agents and potential enrollment in clinical trials.
- As CLL can evolve, it is important to periodically re-evaluate the patient’s status and adjust management plans accordingly.
- Consider the score as part of a holistic assessment that includes other prognostic markers and patient factors to guide therapy selection.